Immunotherapy With Racotumomab in Advanced Lung Cancer
A Prospective, Randomized, Multicenter, Open Label Phase III Study of Active Specific Immunotherapy With Racotumomab Plus Best Support Treatment Versus Best Support Treatment in Patients With Advanced Non-small Cell Lung Camcer.
Sponsor: CIMAB (Cuba)
This PHASE3 trial investigates Lung Cancer, Non-small Cell and NSCLC and is currently ongoing. CIMAB (Cuba) leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
May 2020 — Jan 2021 [monthly]
Unknown Status PHASE3
▶ Show 3 earlier versions
-
Aug 2018 — May 2020 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CIMAB (Cuba)
- Eurofarma Laboratorios S.A.
- Innogene Kalbiotech Pte. Ltd
- Laboratorio Elea Phoenix S.A.
- Recombio SL
For direct contact, visit the study record on ClinicalTrials.gov .